For example, the polo-like kinase 1 (PLK1) inhibitor, BI2536, enhances the chemical sensitivity of cisplatin by inducing pyroptosis in esophageal squamous cell carcinoma, and cisplatin combined with BI2536 can induce pyroptosis in esophageal squamous cell carcinoma at low doses [80]. This evidence concerns the gene PLK1 and esophageal squamous cell carcinoma.